

## Journal Contents Bulletin

Issue 252

28 May 1999

### Notes

In this fortnightly bulletin the main pharmacy related journals held at the South Thames Regional Drug Information Centre are reviewed and articles that are drug related are indexed..

A number of these journals are held in libraries within the region. Please check your local library for further information.

NB: To comply with copyright regulations no more than one article from any one issue of a journal can be supplied to a single individual.

### Contact

Jane Caisley  
South Thames Regional Drug Information Centre  
Guy's Hospital  
St.Thomas Street  
London, SE1 9RT

Tel: 0171 955 5000 Ext: 5892

Fax: 0171 955 2927

Email: [Jane.Caisley@gstt.sthames.nhs.uk](mailto:Jane.Caisley@gstt.sthames.nhs.uk)

### Content

- 1 [Gastrointestinal system](#)
- 2 [Cardiovascular system](#)
- 3 [Respiratory system](#)
- 4 [Central Nervous System](#)
- 5 [Infections \(to include HIV\)](#)
- 6 [Endocrine system](#)
- 7 [Obstetrics, gynaecology & genito-urinary](#)
- 8 [Malignant disease & immunosuppression](#)
- 9 [Nutrition & blood](#)
- 10 [Musculoskeletal & joint diseases](#)
- 11 [Eye](#)
- 12 [Ear, nose and throat](#)
- 13 [Skin & wound care](#)
- 14 [Immunological products & vaccines](#)
- 15 [Anaesthetics & intensive care](#)
- 16 [Adverse effects & poisoning](#)
- 17 [Paediatrics](#)
- 18 [Pain & palliative care](#)
- 19 [Elderly](#)
- 20 [Drug interaction](#)
- 21 [Liver disease](#)
- 22 [Renal diseases](#)
- 23 [Pregnancy & lactation](#)
- 24 [Drug compatibility/stability](#)
- 25 [Wound management](#)
- 26 [Drug misuse/abuse](#)
- 27 [Economics & formularies](#)
- 28 [Pharmacokinetics](#)
- 29 [Pharmacy management](#)
- 30 [Pharmacy practice](#)
- 31 [Alternative and Herbal Medicine](#)

## CONTENTS (based on BNF chapters and appendices)

### 1. Gastrointestinal system

Infliximab retreatment caution advised

*(AJHP 1 Jan 99; 56: 11)*

Omeprazole and lansoprazole suspensions for nasogastric administration

*(AJHP 1 Jan 99; 56: 81)*

\*Management of adolescent and adult inpatients with cystic fibrosis

*(AJHP 15 Jan 99; 56: 158)*

ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis

*(AJHP 15 Feb 99; 56: 347)*

What's the 'best buy' for treatment of constipation? Results of a systematic review of the efficacy and comparative efficacy of laxatives in the elderly

*(B J Gen Pract May 99; 49: 387)*

Infliximab for the treatment of fistulas in patients with Crohn's Disease

*(NEJM 6 May 99; 340: 1398)*

*Helicobacter pylori* and nonulcer dyspepsia

*(NEJM 13 May 99; 340: 1508)*

How to heal fistulas in Crohn's disease

*(Lancet 15 May 99; 353: 1683)*

Management of peptic ulcers in general practice

*(Prescriber 19 April 99 page 75)*

\*Cost effective prescribing in the management of peptic ulcers

*(Prescriber 19 April 99 page 84)*

IBD: drug management of colitis and Crohn's disease

*(Prescriber 5 May 99 page 102)*

Guide to prevention and treatment of haemorrhoids

*(Prescriber 19 May page 77)*

### 2. Cardiovascular system

Four-drug regimen recommended for most heart failure patients

*(AJHP 15 Mar 99; 56: 503)*

Intravenous clonidine for hypertensive emergencies

*(AJHP 15 Mar 99; 56: 572)*

\*Grapefruit juice might still be factor in warfarin response

Issue number 252 Date May 99

**(AJHP 1 Apr 99; 56: 676)**

Contemporary Utilization of Digoxin in Patients with Atrial Fibrillation  
**(Ann Pharmacol Mar 99; 33: 289)**

\*INR Elevation Associated with Diarrhea in a Patient Receiving Warfarin  
**(Ann Pharmacol Mar 99; 33: 301)**

Retepase: A New Thrombolytic for the Treatment of Acute Myocardial Infarction  
**(Ann Pharmacol Mar 99; 33: 318)**

Epoprostenol in Primary Pulmonary Hypertension  
**(Ann Pharmacol Mar 99; 33: 340)**

\*Interaction of ACE Inhibitors and Aspirin in Patients with congestive Heart Failure  
**(Ann Pharmacol Mar 99; 33: 375)**

\*Elevation of Serum Creatinine Following Fosinopril Therapy  
**(Ann Pharmacol Mar 99; 33: 382)**

\*The Use of Alteplase in a Newborn Receiving Extracorporeal Membrane Oxygenation  
**(Ann Pharmacol Apr 99; 33: 416)**

\*Probable Antagonism of Warfarin by Green Tea  
**(Ann Pharmacol Apr 99; 33: 426)**

Streptokinase and Urokinase for the Treatment of Pleural Effusions and Empyemas  
**(Ann Pharmacol Apr 99; 33: 495)**

\*Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen  
**(Ann Pharmacol Apr 99; 33: 506)**

Managing atrial fibrillation in elderly people  
**(BMJ 24 Apr 99; 318: 1088)**

\*Cholesterol screening and management guidelines  
**(BMJ 24 Apr 99; 318: 1140)**

Antihypertensives cut left ventricular hypertrophy  
**(BMJ 1 May 99; 318: 1163)**

Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation  
**(BMJ 15 May 99; 318: 1324)**

\*Fortnightly review: Management of hypertension in pregnancy  
**(BMJ 15 May 99; 318: 1332)**

Evidence based cardiology: Emerging approaches in preventing cardiovascular disease  
**(BMJ 15 May 99; 318: 1337)**

Evidence based cardiology: Prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction  
**(BMJ 22 May 99; 318: 1400)**

Issue number 252 Date May 99

- Prediction of cardiovascular risk  
(*BMJ 22 May 99; 318: 1418*)
- Secondary prevention in coronary heart  
(*BMJ 22 May 99; 318: 1419*)
- Barriers to optimum management of heart failure by general practitioners  
(*B J Gen Pract May 99; 49: 353*)
- \*Current Clinical Use of Reteplase for Thrombolysis: A Pharmacokinetic Pharmacodynamic Perspective  
(*Clin Pkin May 99; 36: 265*)
- Fluvastatin: A Review of its Use in Lipid Disorders  
(*Drugs Apr 99; 57: 583*)
- Nebivolol in the Management of Essential Hypertension: A Review  
(*Drugs Apr 99; 57: 633*)
- Renal protection and antihypertensive drugs: a current status  
(*Drugs May 99; 57: 665*)
- Epidemiology of risk factors for hypertension; implications for prevention and therapy  
(*Drugs May 99; 57: 695*)
- Heart rate as a risk factor atherosclerosis and cardiovascular mortality: the effect of antihypertensive drugs  
(*Drugs May 99; 57: 713*)
- Valsartan/Hydrochlorothiazide  
(*Drugs May 99; 57: 751*)
- Valsartan/Hydrochlorothiazide: viewpoints  
(*Drugs May 99; 57: 756*)
- New antithrombotic agents  
(*Lancet 24 Apr 99; 353: 1431*)
- Coronary heart disease: where have we been and where are we going?  
(*Lancet 8 May 99; 353:1540*)
- What is "hypertension"?  
(*Lancet 8 May 99; 353:1541*)
- Prospects for therapy of nitrate tolerance  
(*Lancet 8 May 99; 353:1545*)
- \*Neurological complications in heparin-induced thrombocytopenia  
(*Lancet 15 May 99; 353:1678*)
- Deep vein thrombosis  
(*Lancet 15 May 99; 353:1708*)
- \*Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin  
(*Lancet 22 May 99; 353: 1763*)

Issue number 252 Date May 99

\*Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis  
(*Lancet* 22 May 99; 353: 1802)

Trends in the prevalence of hypertension, antihypertensive therapy and left ventricular hypertrophy from 1950 to 1989  
(*NEJM* 22 Apr 99; 340: 1221)

\*Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure  
(*NEJM* 29 Apr 99; 340: 1321)

Anti-thrombotic therapy after coronary stenting  
(*NEJM* 29 Apr 99; 340: 1365)

Inadequate management of blood pressure in a hypertensive population  
(*NEJM* 20 May 99; 340: 1593)

Benefit of abciximab in patients with refractory unstable angina in relation to serum Troponin T levels  
(*NEJM* 27 May 99; 340: 1623)

\*The impact of first-line antihypertensive drugs on erectile dysfunction  
(*Pharmacotherapy* May 99; 19: 573)

\*Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease  
(*Pharmacotherapy* May 99; 19: 612)

Anti-ischemic therapy in patients with coronary heart disease living in long-term care  
(*Pharmacotherapy* May 99; 19: 627)

Patterns of prescribing ACE inhibitors after myocardial infarction  
(*Pharmacotherapy* May 99; 19: 627)

\*Lipid-lowering: a good case for a PCG approach  
(*Prescriber* 5 May 99 page 77)

Placing CAPP in perspective (*Prescriber* 19 May 99 page 13)

\*Management of deep vein thrombosis in the elderly  
(*Prescriber* 19 May 99 page 19)

Aspirin: 100 years old and still looking good  
(*Prescriber* 19 May 99 page 29)

\*Drugs that can cause cardiovascular problems  
(*Prescriber* 19 May 99 page 41)

Management of angina  
(*Prescriber* 19 May 99 page 103)

### **3. Respiratory system**

\*Management of adolescent and adult inpatients with cystic fibrosis  
(*AJHP* 15 Jan 99; 56: 161)

Long-term heavy use of diphenhydramine without anticholinergic delirium

Issue number 252 Date May 99

*(AJHP 15 Mar 99; 56: 555)*

\*Potential Metabolic Interaction Between St. John's Wort and Theophylline  
*(Ann Pharmacol Apr 99; 33: 502)*

Clustered randomised trial of an intervention to improve the management of asthma:  
Greenwich asthma study *(BMJ 8 May 99; 318: 1251)*

\*Sequential randomised and double blind trial of promethazine prophylaxis against early  
anaphylactic reactions to antivenom for bothrops snake bites  
*(BMJ 29 May 99; 318: 1451)*

Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages <  
500 micrograms per day in adults and adolescents with mild to moderate asthma  
*(Drugs May 99; 57: 769)*

\*Comparative tolerability of second generation antihistamines  
*(Drug Safety May 99; 20: 385)*

Idiopathic pulmonary fibrosis: new treatment options needed  
*(Drugs & Therapy Perspec 10 May 99; 13: 4)*

\*Do antileukotrienes uncover Churg-Strauss syndrome?  
*(Drugs & Therapy Perspec 24 May 99; 13: 14)*

Asthma exacerbations *(Lancet 24 Apr 99; 353: 1443)*

## 4. Central Nervous system

\*Fatal liver injury reported with tolcapone  
*(AJHP Jan 99; 56: 8)*

\*Determining the most economical SSRI for a Medicare risk contract  
*(AJHP Jan 99; 56: 23)*

\*Phenobarbital for alcohol withdrawal syndrome  
*(AJHP 15 Jan 99; 56: 175)*

Ropinirole: a dopamine agonist for the treatment of Parkinson's disease  
*(AJHP 1 Feb 99; 56: 217)*

\*Stability of lamotrigine in two extemporaneously prepared oral suspensions  
*(AJHP 1 Feb 99; 56: 240)*

Splitting bupropion extended-release tablets  
*(AJHP 15 Mar 99; 56: 575)*

Improving antiemetic prophylaxis in ambulatory surgery  
*(AJHP 15 Apr 99; 56: 728)*

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in  
Adult and Paediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing  
Surgery *(AJHP 15 Apr 99; 56:729)*

Issue number 252 Date May 99

- \*Rhabdomyolysis Associated with Naltrexone  
(*Ann Pharmacol Mar 99; 33: 312*)
- \*Risperidone-Induced Mania  
(*Ann Pharmacol Mar 99; 33: 380*)
- \*Acute Liver Damage Possibly Related to Sertraline and Venlafaxine Ingestion  
(*Ann Pharmacol Mar 99; 33: 381*)
- \*A Critical Review of Selected Pharmacoeconomic Analyses of Antidepressant Therapy  
(*Ann Pharmacol Mar 99; 33: 364*)
- \*Acute Dystonia Associated with Fluvoxamine-Metoclopramide  
(*Ann Pharmacol Mar 99; 33: 382*)
- \*Phenobarbital Dosing in a Neonate Receiving Extracorporeal Membrane Oxygenation  
(*Ann Pharmacol Apr 99; 33: 419*)
- Domperidone  
(*Ann Pharmacol Apr 99; 33: 429*)
- Cholinesterase Inhibitors for Alzheimer Disease  
(*Ann Pharmacol Apr 99; 33: 441*)
- \*Significant Interactions with New Antiretrovirals and Psychotropic Drugs  
(*Ann Pharmacol Apr 99; 33: 461*)
- Indirect Modulation of Dopamine D<sub>2</sub> Receptors as Potential Pharmacotherapy for Schizophrenia: 1. Adenosine Agonists  
(*Ann Pharmacol Apr 99; 33: 480*)
- \*Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen  
(*Ann Pharmacol Apr 99; 33: 506*)
- Science, medicine, and the future: Motor neurone disease  
(*BMJ 24 Apr 99; 318: 1118*)
- \*Drug points: Hepatotoxicity associated with zolpidem treatment  
(*BMJ 1 May 99; 318: 1179*)
- \*Agranulocytosis associated with lamotrigine  
(*BMJ 1 May 99; 318: 1179*)
- Fortnightly review: Drug treatment of depression  
(*BMJ 1 May 99; 318: 1188*)
- \*Drugs for epilepsy have teratogenic risks  
(*BMJ 8 May 99; 318: 1289*)
- \*Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug  
(*Clin Pharmacol Ther 99; 36: 277*)
- Systematic Review and Guide to Selection of Selective Serotonin Reuptake Inhibitors  
(*Drugs Apr 99; 57: 507*)
- \*Treatment of Epilepsy in Pregnancy

Issue number 252 Date May 99

**(Drugs Apr 99; 57: 535)**

Mirtazapine: A Review of its Use in Major Depression  
**(Drugs Apr 99; 57: 607)**

\*Safety issues concerning the use of disulfiram in treating alcohol dependence  
**(Drug Safety May 99; 20: 427)**

Treating depression in patients with ischaemic heart disease: which agents are best to use and to avoid?  
**(Drug Safety May 99; 20: 459)**

\*Tailor drug choice to headache severity in acute migraine attack  
**(Drugs & Therapy Perspec 24 May 99; 13: 8)**

Developments in the treatment of Parkinson's disease  
**(DTB May 99; 37: 36)**

\*Clumsiness, confusion, coma and valproate  
**(Lancet 24 Apr 99; 353: 1408)**

Schizophrenia  
**(Lancet 24 Apr 99; 353: 1425)**

Fluvoxamine reduces social phobia  
**(Lancet 8 May 99; 353:1595)**

Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease  
**(Lancet 22 May 99; 353:1764)**

Buccal midazolam and rectal diazepam for epilepsy  
**(Lancet 22 May 99; 353: 1796)**

\*Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial  
**(Pharmacoeconomics May 99; 15:469)**

\*Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy: following selective serotonin reuptake inhibitor therapy for depression  
**(Pharmacoeconomics May 99; 15:495)**

Gabapentin: a review of published experience in the treatment of bipolar and other psychiatric conditions  
**(Pharmacotherapy May 99; 19: 565)**

\*Carbamazepine-induced hepatorenal failure in a child  
**(Pharmacotherapy May 99; 19: 667)**

Depressing news about the treatment of depression  
**(Prescriber 19 April 99 page 13)**

\*Use of antidepressants in pregnancy and lactation  
**(Prescriber 19 April 99 page 101)**

Tiagabine: add-on therapy for partial seizures  
**(Prescriber 5 May 99 page 19)**

- \*Causes and treatment of insomnia in the elderly  
(*Prescriber 5 May 99 page 39*)

## **5. Infections (to include HIV)**

- \*Development and preliminary outcomes of a program for administering antimicrobials by IV push in home care  
(*AJHP 1 Jan 99; 56: 76*)
- \*Relationships between aminoglycoside and vancomycin pharmacokinetics in patients with hematopoietic stem-cell transplants  
(*AJHP 15 Jan 99; 56: 161*)
- \*Stability of terbinafine hydrochloride in an extemporaneously prepared oral suspension at 25 and 4°C  
(*AJHP 1 Feb 99; 56: 243*)
- \*Stability of high-dose vancomycin and ceftazidime in peritoneal dialysis solutions  
(*AJHP 1 Feb 99; 56: 246*)
- Simultaneous use of two protease inhibitors in HIV infection  
(*AJHP 1 Feb 99; 56: 273*)
- \*Newly approved abacavir to carry hypersensitivity warning  
(*AJHP 15 Feb 99; 56: 304*)
- \*Stability of rifabutin in two extemporaneously compounded oral liquids  
(*AJHP 15 Feb 99; 56: 333*)
- Azithromycin-induced hearing loss  
(*AJHP 15 Feb 99; 56: 380*)
- Medicine is changing- so are the bugs  
(*AJHP 15 Mar 99; 56: 523*)
- The changing face of nosocomial candidemia: Epidemiology, resistance and drug therapy  
(*AJHP 15 Mar 99; 56: 525*)
- New cases of vancomycin-intermediate MRSA infection reported  
(*AJHP 15 Apr 99; 56: 705*)
- Nonprescription and Alternative Medication Use by Individuals with HIV Disease  
(*Ann Pharmaco Mar 99; 33: 294*)
- \*Fatal Stevens-Johnson Syndrome in an AIDS Patient Treatment with Sulfadiazine  
(*Ann Pharmaco Mar 99; 33: 379*)
- Nelfinavir Mesylate: A Protease Inhibitor  
(*Ann Pharmaco Mar 99; 33: 325*)
- Failure of TMP/SMX in the Treatment of PCP  
(*Ann Pharmaco Apr 99; 33: 413*)

Issue number 252 Date May 99

- \*Pentamidine-Induced Hemolytic Anemia in an AIDS Patient  
(*Ann Pharmacol Apr 99; 33: 503*)
  
- \*Significant Interactions with New Antiretrovirals and Psychotropic Drugs  
(*Ann Pharmacol Apr 99; 33: 461*)
  
- Prescribing antibiotics for sore throats  
(*BMJ 24 Apr 99; 318: 1138*)
  
- Prophylaxis against malaria  
(*BMJ 24 Apr 99; 318: 1139*)
  
- \*Pregnancy does not mean that patients with tuberculosis must stop treatment  
(*BMJ 8 May 99; 318: 1286*)
  
- Head lice can be controlled without application of insecticide lotions  
(*BMJ 22 May 99; 318: 1422*)
  
- Foodborne viral infections      (*BMJ 29 May 99; 318: 1433*)
  
- Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used to Treat Patients with HIV Infection      (*Clin Pharmacol Ther May 99; 66: 289*)
  
- Current Guidelines for the Treatment of Patients with Rheumatic Fever  
(*Drugs Apr 99; 57: 545*)
  
- Cytomegalovirus reactivation in patients infected with HIV: the use of polymerase chain reaction in prediction and management  
(*Drugs May 99; 57: 735*)
  
- \*Practical recommendations for the drug treatment of bacterial infections of the male genital tract including urethritis, epididymitis and prostatitis  
(*Drugs May 99; 57: 743*)
  
- Piperacillin/Tazobactam: an updated review of its use in the treatment of bacterial infections  
(*Drugs May 99; 57: 805*)
  
- \*A risk-benefit assessment of HIV protease inhibitors  
(*Drug Safety Apr 99; 20: 299*)
  
- \*The treatment of advanced prostate cancer with ketoconazole: safety issues  
(*Drug Safety May 99; 20: 451*)
  
- Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d' Ivoire  
(*Lancet 1 May 99; 353: 1463*)
  
- Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1 infected patients with tuberculosis in Cote d' Ivoire  
(*Lancet 1 May 99; 353: 1469*)
  
- Community acquired pneumonia  
(*Lancet 1 May 99; 353: 1528*)

Issue number 252 Date May 99

Vancomycin in surgical infections due to methicillin-resistant *Staph aureus* with heterogeneous resistance to vancomycin

(*Lancet* 8 May 99; 353:1587)

Ciprofloxacin-resistant *Salmonella typhi* and treatment failure

(*Lancet* 8 May 99; 353:1590)

\*Therapeutic vaccines for preventing AIDS: their use with HAART

(*Lancet* 22 May 99; 353: 1723)

\* Therapeutic immunisation with recombinant gp160 in HIV-1 infection

(*Lancet* 22 May 99; 353: 1735)

\*Sexual dysfunction with protease inhibitors

(*Lancet* 22 May 99; 353: 1802)

Drug therapy: antiviral drugs (*NEJM* 22 Apr 99; 340: 1255)

\*Terbinafine and fulminant hepatic failure

(*NEJM* 22 Apr 99; 340: 1292)

Discontinuation of primary prophylaxis against *Pneumocystis carinii* pneumonia in HIV-1 infected adults with combination antiretroviral therapy

(*NEJM* 29 Apr 99; 340: 1301)

\*Indinavir crystalluria

(*NEJM* 29 Apr 99; 340: 1329)

Does *Pneumocystis carinii* prophylaxis still need to be lifelong?

(*NEJM* 29 Apr 99; 340: 1356)

\*Valaciclovir for the prevention of cytomegalovirus disease after renal transplantation

(*NEJM* 13 May 99; 340: 1462)

Atovaquone compared with dapsone to prevent *Pneumocystis carinii* pneumonia

(*NEJM* 13 May 99; 340: 1512)

Quinolone-resistant *Campylobacter jejuni* infections in Minnesota 1992-1998

(*NEJM* 20 May 99; 340: 1525)

The consequences for food safety of the use of fluoroquinolones in food animals

(*NEJM* 20 May 99; 340: 1581)

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

(*NEJM* 27 May 99; 340: 1605)

Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy

(*NEJM* 27 May 99; 340: 1614)

Residual HIV-1 disease in the era of highly active antiretroviral therapy

(*NEJM* 27 May 99; 340: 1672)

Control of HIV despite the discontinuation of antiretroviral therapy

(*NEJM* 27 May 99; 340: 1683)

Issue number 252 Date May 99

- Prophylactic antibiotics for severe acute pancreatitis: the beginning of an era  
(*Pharmacotherapy May 99; 19: 593*)
- \*Itraconazole in cyclodextrin solution  
(*Pharmacotherapy May 99; 19: 603*)
- A pilot study of the efficacy of constant-infusion Ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis  
(*Pharmacotherapy May 99; 19: 620*)
- Experience with ceftazidime parenteral-to parenteral dosage stepdown in empiric treatment febrile neutropenia  
(*Pharmacotherapy May 99; 19: 641*)
- \*Economic evaluation of three methods of treating urogenital chlamydial infections in the emergency department  
(*Pharmacotherapy May 99; 19: 648*)
- Mycobacterium fortuitum* meningitis associated with an epidural catheter: case report and a review of the literature  
(*Pharmacotherapy May 99; 19: 661*)
- \*Critical pathways or treatment algorithms in infectious diseases: do they really work  
(*Pharmacotherapy May 99; 19: 672*)
- \*Guide to the treatment and prevention of cystitis  
(*Prescriber 19 April 99 page 39*)
- Antibiotics and upper respiratory tract infections  
(*Prescriber 19 April 99 page 46*)
- \*Cost effective prescribing in upper respiratory tract infections  
(*Prescriber 19 April 99 page 57*)
- Diagnosis and treatment of meningococcal septicaemia  
(*Prescriber 19 April 99 page 95*)
- Management of UTIs  
(*Prescriber 19 April 99 page 125*)
- \*Delayed scripts may reduce antibiotic consumption  
(*Prescriber 5 May 99 page 27*)

## 6. Endocrine system

- Physician attitudes toward human growth hormone products  
(*AJHP Jan 99; 56: 51*)
- \*Expensive lesson in administration of goserelin implant  
(*AJHP 1 Feb 99; 56: 277*)
- \*Therapeutic interchange of conjugated and esterified estrogens in a managed care organization  
(*AJHP 15 Mar 99; 56: 537*)
- \*Safety of insulin lispro: Pooled data from clinical trials

Issue number 252 Date May 99

*(AJHP 15 Mar 99; 56: 542)*

\*Growth hormone found effective in short, healthy children  
*(AJHP 1 Apr 99; 56: 607)*

Compliance with Sulfonylureas in a Health Maintenance Organization: A Pharmacy Record-Based Study  
*(Ann Pharmacol Mar 99; 33: 281)*

Home Blood Glucose Monitoring  
*(Ann Pharmacol Mar 99; 33: 355)*

\*Allergic-Type reactions to Corticosteroids  
*(Ann Pharmacol Apr 99; 33: 451)*

\*Calcitonin in Phantom Limb Pain  
*(Ann Pharmacol Apr 99; 33: 499)*

\*Vaccination and type 1 diabetes mellitus  
*(BMJ 1 May 99; 318: 1159)*

\*Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study  
*(BMJ 1 May 99; 318: 1169)*

\*Management of pituitary tumours  
*(BMJ 8 May 99; 318: 1226)*

Prevention of corticosteroid induced osteoporosis  
*(BMJ 22 May 99; 318: 1366)*

Selective Estrogen receptor modulators: a look ahead  
*(Drugs May 99; 57: 653)*

Insulin Aspart  
*(Drugs May 99; 57: 759)*

Insulin Aspart: viewpoints  
*(Drugs May 99; 57: 759)*

\*Lactic acidosis in metformin-treated patients: prognostic value of arterial lactate levels and plasma metformin concentrations  
*(Drug Safety Apr 99; 20: 377)*

Raloxifene to prevent postmenopausal osteoporosis  
*(DTB May 99; 37: 33)*

\*Effect of antenatal betamethasone administration on placental vascular resistance  
*(Lancet 24 Apr 99; 353: 1404)*

Hormone replacement therapy in postmenopausal women and cardiovascular risk  
*(Lancet 1 May 99; 353: 1528)*

Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms  
*(Lancet 8 May 99; 353:1574)*

The role of dehydroepiandrosterone in diabetes mellitus  
*(Pharmacotherapy May 99; 19: 582)*

Issue number 252 Date May 99

Treating Type 2 diabetes (*Prescriber 5 May 99 page 121*)

## **7. Obstetrics, Gynaecology and Genito-urinary disorders**

\*Adverse Reactions to drugs used for erectile dysfunction  
(*ADR Bulletin April 99 No 195*)

\*Chronic pelvic pain syndrome (*BMJ 8 May 99; 318: 1227*)

Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study  
(*BMJ 8 May 99; 318: 1246*)

UK government finalises Viagra restrictions  
(*BMJ 15 May 99; 318: 1305*)

\*Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review  
(*BMJ 22 May 99; 318: 1375*)

Finasteride: An Update of its use in the Management of Symptomatic Benign Prostatic Hyperplasia  
(*Drugs Apr 99; 57: 557*)

\*Practical recommendations for the drug treatment of bacterial infections of the male genital tract including urethritis, epididymitis and prostatitis  
(*Drugs May 99; 57: 743*)

\*A risk-benefit assessment of oxytocics in obstetric practice  
(*Drug Safety Apr 99; 20: 323*)

Finasteride: oral therapy preserves crowning glory  
(*Drugs & Therapy Perspec 24 May 99; 13: 1*)

\*Effect of antenatal betamethasone administration on placental vascular resistance  
(*Lancet 24 Apr 99; 353: 1404*)

\*Retinal side-effects of sildenafil  
(*Lancet 24 Apr 99; 353: 1442*)

\*Oral-contraceptive use and risk of hip fracture  
(*Lancet 1 May 99; 353: 1481*)

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome  
(*NEJM 29 Apr 99; 340: 1314*)

Imiquimod: self-treatment for anogenital warts  
(*Prescriber 19 April 99 page 21*)

\*Guide to the treatment and prevention of cystitis  
(*Prescriber 19 April 99 page 39*)

## 8. Malignant disease and immunosuppression

- \*Expensive lesson in administration of goserelin implant  
(*AJHP 1 Feb 99; 56: 277*)
- Cytotoxic protein approved for cutaneous T-cell lymphoma  
(*AJHP 15 Mar 99; 56:502*)
- FDA approves topical treatment for cutaneous lesions of Kaposi's sarcoma  
(*AJHP 1 Apr 99; 56: 603*)
- Combined chemotherapy-radiation therapy recommended for invasive cervical cancer  
(*AJHP 15 Apr 99; 56: 702*)
- \*Ototoxicity Associated with Vinblastine  
(*Ann Pharmacol Apr 99; 33: 423*)
- Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials  
(*BMJ 24 Apr 99; 318: 1104*)
- \*Drug points: Cyclosporin neurotoxicity after chemotherapy  
(*BMJ 24 Apr 99; 318: 1113*)
- Chemotherapy and radiotherapy for locally advanced cervical cancer  
(*BMJ 1 May 99; 318: 1161*)
- \*Management of pituitary tumours  
(*BMJ 8 May 99; 318: 1226*)
- High dose chemotherapy of little benefit in breast cancer  
(*BMJ 29 May 99; 318: 1437*)
- \*Cardiotoxicity of the Antiproliferative Compound Fluorouracil  
(*Drugs Apr 99; 57: 475*)
- Current Drug Therapy for Multiple Myeloma  
(*Drugs Apr 99; 57: 485*)
- Photodynamic therapy in the treatment of cancer: current state of the art  
(*Drugs May 99; 57: 725*)
- \*Drugs hazardous to healthcare workers: evaluation of methods for monitoring occupational exposure to cytostatic drugs  
(*Drug Safety Apr 99; 20: 347*)
- \*A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma  
(*Drug Safety May 99; 20: 403*)
- \*Cyclosporin-induced hypertension: incidence, pathogenesis and management  
(*Drug Safety May 99; 20: 437*)
- \*The treatment of advanced prostate cancer with ketoconazole: safety issues

Issue number 252 Date May 99

**(Drug Safety May 99; 20: 451)**

Topotecan worth trying in advanced ovarian cancer if first-line therapy fails  
**(Drugs & Therapy Perspec 10 May 99; 13: 1)**

\*Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients  
**(Lancet 24 Apr 99; 353: 1413)**

Immunotherapy for colon cancer  
**(Lancet 1 May 99; 353: 1524)**

Chaos surrounds high-dose chemotherapy for breast cancer  
**(Lancet 15 May 99; 353:1633)**

BCG immunotherapy of bladder cancer: 20 years on  
**(Lancet 15 May 99; 353:1689)**

Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen  
**(Lancet 15 May 99; 353:1641)**

Tacrolimus in refractory polymyositis with interstitial lung disease  
**(Lancet 22 May 99; 353: 1762)**

\*Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis  
**(Lancet 22 May 99; 353: 1802)**

\*Prediction of the depressive effects of Interferon alfa therapy by the patient's initial affective state  
**(NEJM 29 Apr 99; 340: 1370)**

Treatment of acute myeloid leukemia  
**(NEJM 6 May 99; 340: 1436)**

Long acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer  
**(NEJM 6 May 99; 340: 1439)**

Treatment of esophageal cancer  
**(NEJM 27 May 99; 340: 1685)**

## **9. Nutrition and Blood**

Nonabsorbable polymer marketed as phosphate binder  
**(AJHP 1 Jan 99; 56: 11)**

Preparing for parenteral nutrition therapy at home  
**(AJHP 1 Feb 99; 56: 270)**

Research fails to support TPN use in critically ill patients  
**(AJHP 15 Feb 99; 56: 310)**

New IV iron product to be introduced  
**(AJHP 15 Apr 99; 56: 706)**

Issue number 252 Date May 99

\*Implementation of safe practices for parenteral nutrition formulations  
(*AJHP 15 Apr 99; 56: 815*)

Glutamine Supplementation in Catabolic Patients  
(*Ann Pharmacol Mar 99; 33: 348*)

\*Unusual Toxicity of Deferoxamine  
(*Ann Pharmacol Apr 99; 33: 505*)

Recommended intake of vitamin C increased  
(*BMJ 1 May 99; 318: 1163*)

More on albumin (*BMJ 1 May 99; 318: 1214*)

Vitamin D deficiency (*BMJ 8 May 99; 318: 1284*)

Albumin again (*BMJ 15 May 99; 318: 1352*)

\*Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review  
(*BMJ 22 May 99; 318: 1375*)

Vitamin B12 deficiency and nitrous oxide  
(*Lancet 1 May 99; 353: 1529*)

Trace elements linked to cardiomyopathy  
(*Lancet 8 May 99; 353:1594*)

The effect of folic acid fortification on plasma folate and total homocysteine concentrations  
(*NEJM 13 May 99; 340: 1449*)

## 10. Musculoskeletal and joint diseases

Decisions loom on selective COX-2 inhibitors  
(*AJHP 15 Jan 99; 56:106*)

\*Glucosamine sulfate use in osteoarthritis  
(*AJHP 1 Feb 99; 56: 267*)

Effects of NSAIDs on bone healing have been widely reported in maxillofacial journals  
(*BMJ 24 Apr 99; 318: 1141*)

Osteoarthritis: time to shift the paradigm  
(*BMJ 15 May 99; 318: 1299*)

Treatment of shoulder complaints in general practice: long term results of a randomised, single blind study comparing physiotherapy, manipulation, and corticosteroid injection  
(*BMJ 22 May 99; 318: 1395*)

COX-2 Inhibitors (*Lancet 24 Apr 99; 353: 1439*)

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis  
(*Lancet 8 May 99; 353:1568*)

Issue number 252 Date May 99

Hyaluronic acid: a new treatment option for OA  
(*Prescriber 19 April 99 page 113*)

Osteoarthritis: current management approaches  
(*Prescriber 19 May 99 page 48*)

\*Cost-effective prescribing of NSAIDs in osteoarthritis  
(*Prescriber 19 May 99 page 58*)

## 11. Eye

## 12. Ear, nose and throat

Intranasal corticosteroids in allergic rhinitis  
(*BMJ 15 May 99; 318: 1350*)

\*Cushing's syndrome induced by betamethasone nose drops  
(*BMJ 15 May 99; 318: 1355*)

\*Treating allergic rhinitis in pregnancy: safety considerations  
(*Drug Safety Apr 99; 20: 361*)

## 13. Skin and Wound Care

\*Identifying severe skin reactions to drug therapy  
(*Prescriber 19 April 99 page 119*)

Psoriasis management within primary care  
(*Prescriber 5 May 99 page 47*)

\*Cost effective prescribing for psoriasis  
(*Prescriber 5 May 99 page 61*)

Guide to diagnosis and management of rosacea  
(*Prescriber 19 May page 97*)

Warts: features and approaches to treatment  
(*Prescriber 19 May page 123*)

## 14. Immunological products and vaccines

Precautions advised for IGIV  
(*AJHP 1 Jan 99; 56: 8*)

Lyme disease vaccine cleared for marketing  
(*AJHP 1 Feb 99; 56: 206*)

\*Immunisation of infants at risk of perinatal transmission of hepatitis B: retrospective audit of vaccine uptake  
(*BMJ 24 Apr 99; 318: 1112*)

\*Vaccination and type 1 diabetes mellitus  
(*BMJ 1 May 99; 318: 1159*)

\*Association between type 1 diabetes and *Haemophilus influenzae* type b vaccination: birth cohort study  
(*BMJ 1 May 99; 318: 1169*)

\*Pertussis vaccination and wheezing illnesses in young children: prospective cohort study  
(*BMJ 1 May 99; 318: 1173*)

\*Vaccines and their real or perceived adverse effects  
(*BMJ 29 May 99; 318: 1487*)

\*Therapeutic vaccines for preventing AIDS: their use with HAART  
(*Lancet 22 May 99; 353: 1723*)

\* Therapeutic immunisation with recombinant gp160 in HIV-1 infection  
(*Lancet 22 May 99; 353: 1735*)

## 15. Anaesthetics and Intensive Care

Issue number 252 Date May 99

Neuromuscular blockade in the intensive care unit  
(*AJHP Jan 99; 56: 72*)

\*Cost analysis of remifentanyl and fentanyl for neurosurgical anesthesia  
(*AJHP 15 Mar 99; 56: 551*)

ABC of intensive care: Organisation of intensive care  
(*BMJ 29 May 99; 318: 1468*)

Epidural analgesia and risk of caesarean section  
(*Lancet 22 May 99; 353:1801*)

## 16. Adverse Effects

\*Adverse Reactions to drugs used for erectile dysfunction  
(*ADR Bulletin April 99 No 195*)

\*Fatal liver injury reported with tolcapone  
(*AJHP Jan 99; 56: 8*)

\*Newly approved abacavir to carry hypersensitivity warning  
(*AJHP 15 Feb 99; 56: 304*)

\*Azithromycin-induced hearing loss  
(*AJHP 15 Feb 99; 56: 380*)

\*Safety of insulin lispro: Pooled data from clinical trials  
(*AJHP 15 Mar 99; 56: 542*)

\*INR Elevation Associated with Diarrhea in a Patient Receiving Warfarin  
(*Ann Pharmacol Mar 99; 33: 301*)

Bupropion Mimics a Transient Ischemic Attack  
(*Ann Pharmacol Mar 99; 33: 305*)

High Anion Gap Metabolic Acidosis Associated with Aminocaproic Acid  
(*Ann Pharmacol Mar 99; 33: 308*)

\*Rhabdomyolysis associated with Naltrexone  
(*Ann Pharmacol Mar 99; 33: 312*)

\*Contamination of Antibiotics Resulting in Severe Paediatric Methadone Poisoning  
(*Ann Pharmacol Mar 99; 33: 314*)

\*Fatal Stevens-Johnson Syndrome in an AIDS Patient Treated with Sulfadiazine  
(*Ann Pharmacol Mar 99; 33: 379*)

\*Risperidone-Induced Mania  
(*Ann Pharmacol Mar 99; 33: 380*)

\*Acute Liver Damage possibly Related to Sertraline and Venlafaxine Ingestion  
(*Ann Pharmacol Mar 99; 33: 381*)

Risk of Latex Allergy from Medication Vial Closures

Issue number 252 Date May 99

**(Ann Pharmacol Mar 99; 33: 373)**

\*Acute Dystonia Associated with Fluvoxamine-Metoclopramide  
**(Ann Pharmacol Mar 99; 33: 382)**

\*Elevation of Serum Creatinine Following Fosinopril Therapy  
**(Ann Pharmacol Mar 99; 33: 382)**

\*Estimating Risk Factors for Potential Drug-Related problems Using Electronic Pharmacy Data  
**(Ann Pharmacol Apr 99; 33: 406)**

\*Ototoxicity Associated with Vinblastine  
**(Ann Pharmacol Apr 99; 33: 423)**

\*Pentamidine-Induced Hemolytic Anemia in an AIDS Patient  
**(Ann Pharmacol Apr 99; 33: 503)**

\*Allergic-Type Reactions to Corticosteroids  
**(Ann Pharmacol Apr 99; 33: 451)**

\*Unusual Toxicity of Deferoxamine  
**(Ann Pharmacol Apr 99; 33: 505)**

\*Drug points: Cyclosporin neurotoxicity after chemotherapy  
**(BMJ 24 Apr 99; 318: 1113)**

\*Children poisoned with illegal drugs in Glasgow  
**(BMJ 24 Apr 99; 318: 1137)**

\*Drug points: Hepatotoxicity associated with zolpidem treatment  
**(BMJ 1 May 99; 318: 1179)**

\*Agranulocytosis associated with lamotrigine  
**(BMJ 1 May 99; 318: 1179)**

Areca nuts can have deleterious effects  
**(BMJ 8 May 99; 318: 1287)**

\*Cushing's syndrome induced by betamethasone nose drops  
**(BMJ 15 May 99; 318: 1355)**

\*Sequential randomised and double blind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for bothrops snake bites  
**(BMJ 29 May 99; 318: 1451)**

\*Vaccines and their real or perceived adverse effects  
**(BMJ 29 May 99; 318: 1487)**

\*Cardiotoxicity of the Antiproliferative Compound Fluorouracil  
**(Drugs Apr 99; 57: 475)**

Risk of melanoma with psoralen/ultraviolet a therapy for psoriasis: do the known risks now outweigh the benefits?  
**(Drug Safety Apr 99; 20: 289)**

Issue number 252 Date May 99

- \*A risk-benefit assessment of HIV protease inhibitors  
(*Drug Safety Apr 99; 20: 299*)
  
- \*A risk-benefit assessment of oxytocics in obstetric practice  
(*Drug Safety Apr 99; 20: 323*)
  
- \*Drugs hazardous to healthcare workers: evaluation of methods for monitoring occupational exposure to cytostatic drugs  
(*Drug Safety Apr 99; 20: 347*)
  
- \*Lactic acidosis in metformin-treated patients: prognostic value of arterial lactate levels and plasma metformin concentrations  
(*Drug Safety Apr 99; 20: 377*)
  
- \*Comparative tolerability of second generation antihistamines  
(*Drug Safety May 99; 20: 385*)
  
- \*A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma  
(*Drug Safety May 99; 20: 403*)
  
- \*Safety issues concerning the use of disulfiram in treating alcohol dependence  
(*Drug Safety May 99; 20: 427*)
  
- \*Cyclosporin-induced hypertension: incidence, pathogenesis and management  
(*Drug Safety May 99; 20: 437*)
  
- \*Do antileukotrienes uncover Churg-Strauss syndrome?  
(*Drugs & Therapy Perspec 24 May 99; 13: 14*)
  
- \*Clumsiness, confusion, coma and valproate  
(*Lancet 24 Apr 99; 353: 1408*)
  
- Organophosphate exposure and variant Creutzfeldt-Jakob disease  
(*Lancet 24 Apr 99; 353: 1410*)
  
- \*Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients  
(*Lancet 24 Apr 99; 353: 1413*)
  
- \*Retinal side-effects of sildenafil  
(*Lancet 24 Apr 99; 353: 1442*)
  
- \*New drugs, new adverse drug reactions and bibliographic databases  
(*Lancet 24 Apr 99; 353: 1447*)
  
- \*Oral-contraceptive use and risk of hip fracture  
(*Lancet 1 May 99; 353: 1481*)
  
- \*Neurological complications in heparin-induced thrombocytopenia  
(*Lancet 15 May 99; 353:1678*)
  
- \*Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin  
(*Lancet 22 May 99; 353: 1763*)
  
- \*Sexual dysfunction with protease inhibitors  
(*Lancet 22 May 99; 353: 1802*)

Issue number 252 Date May 99

- Carbon monoxide poisoning  
(*NEJM 22 Apr 99; 340: 1290*)
- \*Terbinafine and fulminant hepatic failure  
(*NEJM 22 Apr 99; 340: 1292*)
- \*Indinavir crystalluria  
(*NEJM 29 Apr 99; 340: 1329*)
- \*Prediction of the depressive effects of Interferon alfa therapy by the patient's initial affective state  
(*NEJM 29 Apr 99; 340: 1370*)
- \*Parkinsonism after taking ecstasy  
(*NEJM 6 May 99; 340: 1443*)
- \*Counting the costs of drug related adverse events  
(*Pharmacoeconomics May 99; 15:445*)
- \*The impact of first-line antihypertensive drugs on erectile dysfunction  
(*Pharmacotherapy May 99; 19: 573*)
- \*Carbamazepine-induced hepatorenal failure in a child  
(*Pharmacotherapy May 99; 19: 667*)
- \*Identifying severe skin reactions to drug therapy  
(*Prescriber 19 April 99 page 119*)
- Adverse drug reactions: effect of drugs on the musculoskeletal system  
(*Prescriber 5 May 99 page 33*)
- \*Drugs that can cause cardiovascular problems  
(*Prescriber 19 May 99 page 41*)

## 17. Paediatrics

- FDA to require pediatric studies for drugs commonly used in children  
(*AJHP 1 Feb 99; 56: 203*)
- Evidence-based medicine for children  
(*AJHP 15 Feb 99; 56: 331*)
- \*Growth hormone found effective in short, healthy children  
(*AJHP 1 Apr 99; 56: 607*)
- \*Contamination of Antibiotics Resulting in Severe Paediatric Methadone Poisoning  
(*Ann Pharmaco Mar 99; 33: 314*)
- \*The Use of Alteplase in a Newborn Receiving Extracorporeal Membrane Oxygenation  
(*Ann Pharmaco Apr 99; 33: 416*)
- \*Phenobarbital Dosing in a Neonate Receiving Extracorporeal Membrane Oxygenation  
(*Ann Pharmaco Apr 99; 33: 419*)

Issue number 252 Date May 99

- \*Children poisoned with illegal drugs in Glasgow  
(*BMJ 24 Apr 99; 318: 1137*)
- \*Pertussis vaccination and wheezing illnesses in young children: prospective cohort study  
(*BMJ 1 May 99; 318: 1173*)
- Neonatal hyperbilirubinaemia: early detection and appropriate treatment prevent kernicterus  
(*Drugs & Therapy Perspec 24 May 99; 13: 11*)
- \*Carbamazepine-induced hepatorenal failure in a child  
(*Pharmacotherapy May 99; 19: 667*)

## 18. Pain and Palliative Care

- \*Calcitonin in Phantom Limb Pain  
(*Ann Pharmaco Apr 99; 33: 499*)
- Evidence based case report: Low back pain: which is the best way forward?  
(*BMJ 24 Apr 99; 318: 1122*)
- \*Chronic pelvic pain syndrome (*BMJ 8 May 99; 318: 1227*)
- \*Tailor drug choice to headache severity in acute migraine attack  
(*Drugs & Therapy Perspec 24 May 99; 13: 8*)
- Exploration of pain (*Lancet 8 May 99; 353:1546*)
- Pain - an overview (*Lancet 8 May 99; 353:1607*)
- The neurobiology of pain (*Lancet 8 May 99; 353:1610*)
- The prevention of postherpetic neuralgia  
(*Lancet 15 May 99; 353:1636*)
- Management of cancer pain (*Lancet 15 May 99; 353:1695*)
- Management of pain in sickle cell disease  
(*Prescriber 19 May 99 page 91*)

## 19. Elderly

- Geriatrics and the limits of modern medicine  
(*NEJM 22 Apr 99; 340: 1283*)
- \*Causes and treatment of insomnia in the elderly  
(*Prescriber 5 May 99 page 39*)
- \*Management of deep vein thrombosis in the elderly  
(*Prescriber 19 May 99 page 19*)

## 20. Drug Interactions

- \*Grapefruit juice might still be factor in warfarin response  
(*AJHP 1 Apr 99; 56: 676*)
- \*Interaction of ACE Inhibitors and Aspirin in Patients with Congestive Heart Failure  
(*Ann Pharmaco Mar 99; 33: 375*)
- \*Acute Dystonia Associated with Fluvoxamine-Metoclopramide  
(*Ann Pharmaco Mar 99; 33: 382*)
- \*Probable Antagonism of Warfarin by Green Tea  
(*Ann Pharmaco Apr 99; 33: 426*)
- \*Potential Metabolic Interaction Between St. John's Wort and Theophylline  
(*Ann Pharmaco Apr 99; 33: 502*)
- \*Significant Interactions with New Antiretrovirals and Psychotropic Drugs  
(*Ann Pharmaco Apr 99; 33: 461*)
- \*Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen  
(*Ann Pharmaco Apr 99; 33: 506*)
- \*Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used to Treat Patients with HIV Infection  
(*Clin Pkin May 99; 36: 289*)

## 21. Liver Disease

- \*Health care costs associated with chronic hepatitis B  
(*AJHP 1 Feb 99; 56: 232*)
- Recent advances: Hepatology (*BMJ 8 May 99; 318: 1256*)

## 22. Renal Disease

Angiotensin-Converting Enzyme Gene Polymorphism: Is there a Link to Nephropathy in Patients with Type 1 Diabetes?

*(Ann Pharmacol Apr 99; 33: 474)*

Glomerulonephritis

*(Lancet 1 May 99; 353: 1509)*

\*Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure

*(NEJM 29 Apr 99; 340: 1321)*

\*Valaciclovir for the prevention of cytomegalovirus disease after renal transplantation

*(NEJM 13 May 99; 340: 1462)*

Reconciling decision models with the real world: an application to anaemia of renal failure

*(Pharmacoeconomics May 99; 15:481)*

\*Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease

*(Pharmacotherapy May 99; 19: 612)*

## 23. Pregnancy and Lactation

\*Pregnancy does not mean that patients with tuberculosis must stop treatment

*(BMJ 8 May 99; 318: 1286)*

\*Drugs for epilepsy have teratogenic risks

*(BMJ 8 May 99; 318: 1286)*

\*Fortnightly review: Management of hypertension in pregnancy

*(BMJ 15 May 99; 318: 1332)*

Women with epilepsy need pregnancy advice

*(BMJ 22 May 99; 318: 1369)*

Treatment of Epilepsy in Pregnancy

*(Drugs Apr 99; 57: 535)*

\*Treating allergic rhinitis in pregnancy: safety considerations

*(Drug Safety Apr 99; 20: 361)*

Alcohol injection: a new method of treating placental chorioangiomas

*(Lancet 15 May 99; 353:1674)*

\*Use of antidepressants in pregnancy and lactation

*(Prescriber 19 April 99 page 101)*

## 24. Drug Compatibility/Stability

Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions

*(AJHP 1 Jan 99; 56: 63)*

\*Stability of lamotrigine in two extemporaneously prepared oral suspensions

Issue number 252 Date May 99

*(AJHP 1 Feb 99; 56: 240)*

Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration

*(AJHP 15 Jan 99; 56: 164)*

Other sources of stability research

*(AJHP 15 Jan 99; 56: 179)*

\*Stability of terbinafine hydrochloride in an extemporaneously prepared oral suspension at 25 and 4°C

*(AJHP 1 Feb 99; 56: 243)*

\*Stability of high-dose vancomycin and ceftazidime in peritoneal dialysis solutions

*(AJHP 1 Feb 99; 56: 246)*

\*Stability of rifabutin in two extemporaneously compounded oral liquids

*(AJHP 15 Feb 99; 56: 333)*

Stability of fumagillin in an extemporaneously prepared ophthalmic solution

*(AJHP 15 Mar 99; 56: 547)*

\*Implementation of safe practices for parenteral nutrition formulations

*(AJHP 15 Apr 99; 56: 706)*

\*Itraconazole in cyclodextrin solution

*(Pharmacotherapy May 99; 19: 603)*

## 25. Wound Management

## 26. Drug Misuse/Abuse

\*Phenobarbital for alcohol withdrawal syndrome

*(AJHP 15 Jan 99; 56: 175)*

Drug misuse stems from a person's autonomy to choose

*(BMJ 24 Apr 99; 318: 1142)*

Sex and Drugs and rock and roll

*(BMJ 15 May 99; 318: 1300)*

Detection of doping

*(Lancet 1 May 99; 353: 1532)*

Controlled clinical evaluation of diacetyl morphine for treatment of intractable opiate dependence

*(Lancet 8 May 99; 353:1543)*

\*Parkinsonism after taking ecstasy

*(NEJM 6 May 99; 340: 1443)*

Drug Therapy: drug therapy for alcohol dependence

*(NEJM 13 May 99; 340: 1482)*

## 27. Economics and Formularies

\*Determining the most economical SSRI for a Medicare risk contract  
(*AJHP 1 Jan 99; 56: 23*)

Projecting future drug expenditures - 99  
(*AJHP 1 Jan 99; 56: 31*)

\*Health care costs associated with chronic hepatitis B  
(*AJHP 1 Feb 99; 56: 232*)

\*Cost analysis of remifentanyl and fentanyl for neurosurgical anesthesia  
(*AJHP 15 Mar 99; 56: 551*)

Nonformulary drug requests as a guide in formulary system management  
(*AJHP 15 Apr 99; 56: 818*)

\*A Critical Review of Selected Pharmacoeconomic Analyses of Antidepressant Therapy  
(*Ann Pharmaco Mar 99; 33: 364*)

\*Not playing with a full DEC: why development and evaluation committee methods for appraising new drugs may be inadequate  
(*BMJ 29 May 99; 318: 1480*)

\*SOJA: a useful tool for formulary decision makers?  
(*Drugs & Therapy Perspec 10 May 99; 13: 8*)

Pharmacoeconomic evaluation in the real world: effectiveness versus efficacy studies  
(*Pharmacoeconomics May 99; 15:423*)

Prescribing at the interface between primary and secondary care in the UK: towards joint formularies?  
(*Pharmacoeconomics May 99; 15:435*)

\*Counting the costs of drug related adverse events  
(*Pharmacoeconomics May 99; 15:445*)

The revised Canadian guidelines for the economic evaluation of pharmaceuticals  
(*Pharmacoeconomics May 99; 15:459*)

\*Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial  
(*Pharmacoeconomics May 99; 15:469*)

\*Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy: following selective serotonin reuptake inhibitor therapy for depression  
(*Pharmacoeconomics May 99; 15:495*)

Direct costs of hip fractures in patients over 60 years of age in Belgium  
(*Pharmacoeconomics May 99; 15: 507*)

Issue number 252 Date May 99

\*Economic evaluation of three methods of treating urogenital chlamydial infections in the emergency department  
(*Pharmacotherapy May 99; 19: 648*)

\*Cost effective prescribing in upper respiratory tract infections  
(*Prescriber 19 April 99 page 57*)

\*Cost effective prescribing in the management of peptic ulcers  
(*Prescriber 19 April 99 page 84*)

\*Cost effective prescribing for psoriasis  
(*Prescriber 5 May 99 page 61*)

\*Cost-effective prescribing of NSAIDs in osteoarthritis  
(*Prescriber 19 May 99 page 58*)

How health economics can facilitate prescribing  
(*Prescriber 19 May page 117*)

## 28. Pharmacokinetics

\*Relationships between aminoglycoside and vancomycin pharmacokinetics in patients with hematopoietic stem-cell transplants  
(*AJHP 15 Jan 99; 56: 161*)

Software for population Pharmacokinetics and Pharmacodynamics  
(*Clin Pkin May 99; 36: 255*)

\*Current Clinical Use of Reteplase for Thrombolysis: A Pharmacokinetic-Pharmacodynamic Perspective  
(*Clin Pkin May 99; 36: 265*)

\*Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug  
(*Clin Pkin May 99; 36: 277*)

\*Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used to Treat Patients with HIV Infection  
(*Clin Pkin May 99; 36: 289*)

\*Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease  
(*Pharmacotherapy May 99; 19: 612*)

## 29. Pharmacy Management

\*Clinical research: Business opportunities for pharmacy-based investigational drug services  
(*AJHP 15 Feb 99; 56: 249*)

Benchmarking the allocation of pharmacists' time  
(*AJHP 15 Mar 99; 56: 516*)

Activities, functions, and structure of pharmacy and therapeutics committees in large teaching hospitals  
(*AJHP 1 Apr 99; 56: 622*)

Role of pharmacists on disaster response teams  
(*AJHP 15 Apr 99; 56: 716*)

Repeat prescribing management- a cause for concern?

Issue number 252 Date May 99

*(B J Gen Pract May 99; 49: 343)*

\*SOJA: a useful tool for formulary decision makers?

*(Drugs & Therapy Perspec 10 May 99; 13: 8)*

\*Provision of treatment for multiple sclerosis

*(Lancet 15 May 99; 353:1710)*

## **30. Pharmacy Practice**

A validated, reliable method of scoring the severity of medication errors

*(AJHP 1 Jan 99; 56: 57)*

\*Development and preliminary outcomes of a program for administering antimicrobials by IV push in home care

*(AJHP 1 Jan 99; 56: 76)*

Mirror to health system pharmacy

*(AJHP 15 Jan 99; 56: 123)*

Clinical research: Managing the issues

*(AJHP 15 Jan 99; 56: 170)*

Clinical research: trends affecting the pharmaceutical industry and the pharmacy profession

*(AJHP 15 Jan 99; 56: 171)*

Rules set for dissemination of off-label-use information

*(AJHP 1 Feb 99; 56: 204)*

Responsibility for medication errors

*(AJHP 1 Feb 99; 56: 215)*

Work patterns of ambulatory care pharmacists with access to electronic guideline-based treatment suggestions

*(AJHP 1 Feb 99; 56: 225)*

Therapeutic selection during an emergency response

*(AJHP 1 Feb 99; 56: 236)*

\*Clinical research: Business opportunities for pharmacy-based investigational drug services

*(AJHP 1 Feb 99; 56: 249)*

The pharmacist and assisted suicide

*(AJHP 1 Feb 99; 56: 260)*

Preparing pharmacy technicians for patient-focused care

*(AJHP 15 Feb 99; 56: 324)*

Clinical research: ASHP guidelines and future directions for pharmacists

*(AJHP 15 Feb 99; 56: 344)*

Internet-based prescribing and dispensing trouble medical and pharmacy boards

*(AJHP 15 Mar 99; 56: 500)*

Issue number 252 Date May 99

\*Therapeutic interchange of conjugated and esterified estrogens in a managed care organization  
(*AJHP 15 Mar 99; 56: 537*)

Establishing realistic performance standards for community pharmacists' drug-use-review activities in managed care contracts  
(*AJHP 15 Mar 99; 56: 566*)

Keeping up with drug information  
(*AJHP 1 Apr 99; 56: 613*)

Transplant pharmacists' opinions on generic product selection of critical-dose drugs  
(*AJHP 1 Apr 99; 56: 615*)

Artificial shortages of drug supplies  
(*AJHP 15 Apr 99; 56: 727*)

Over-the-Counter Drug Prescribing Patterns  
(*Ann Pharmacol Apr 99; 33: 400*)

\*Estimating Risk Factors for Potential Drug-Related Problems Using Electronic Pharmacy Data  
(*Ann Pharmacol Apr 99; 33: 406*)

Managing chronic disease  
(*BMJ 24 Apr 99; 318: 1090*)

Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study  
(*BMJ 24 Apr 99; 318: 1114*)

Clinical trials  
(*BMJ 24 Apr 99; 318: 1138*)

\*Cholesterol screening and management guidelines  
(*BMJ 24 Apr 99; 318: 1140*)

Reporting on quality of life in RCTs  
(*BMJ 24 Apr 99; 318: 1142*)

Guidelines in general practice  
(*BMJ 1 May 99; 318: 1212*)

Use of randomisation in early clinical trials  
(*BMJ 15 May 99; 318: 1352*)

\*Not playing with a full DEC: why development and evaluation committee methods for appraising new drugs may be inadequate  
(*BMJ 29 May 99; 318: 1480*)

Clinical governance- a new label for old ingredients: quality or quantity?  
(*B J Gen Pract May 99; 49: 339*)

\*New drugs, new adverse drug reactions and bibliographic databases  
(*Lancet 24 Apr 99; 353: 1447*)

Clinical Pharmacy: just what the patient ordered  
(*Pharmacotherapy May 99; 19: 555*)

Clinical pharmacy services and hospital mortality rates  
(*Pharmacotherapy May 99; 19: 556*)

Issue number 252 Date May 99

\*Critical pathways or treatment algorithms in infectious diseases: do they really work  
( *Pharmacotherapy May 99; 19: 672*)

Delayed scripts may reduce antibiotic consumption  
(*Prescriber 5 May 99 page 27*)

\*Lipid-lowering: a good case for a PCG approach  
(*Prescriber 5 May 99 page 77*)

Managing trouble-free changes in therapeutics  
(*Prescriber 19 May page 133*)

## **31. Alternative and Herbal medicine**

Unsafe and potentially safe herbal therapies  
(*AJHP 15 Jan 99; 56: 125*)

\*Glucosamine sulfate use in osteoarthritis  
(*AJHP 1 Feb 99; 56: 267*)

St John's wort: *Hypericum perforatum*  
(*AJHP 15 Feb 99; 56: 329*)

Coenzyme Q  
(*AJHP 15 Mar 99; 56: 519*)

\*Nonprescription and Alternative Medication Use by Individuals with HIV Disease  
(*Ann Pharmacol Mar 99; 33: 294*)

\*Probable Antagonism of Warfarin by Green Tea  
(*Ann Pharmacol Apr 99; 33: 426*)

\*Potential Metabolic Interaction Between St. John's Wort and Theophylline  
(*Ann Pharmacol Apr 99; 33: 502*)